US Bancorp’s Actinium Pharmaceuticals ATNM Stock Holding History

US Bancorp’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-21	Closed	-$1K	–	3536
2016 Q3	$1K	Buy	+21	New	+$1.08K	﹤0.01%	3425

Other funds holding ATNM

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

US Bancorp's ATNM Position: Q4 2016 in Review

US Bancorp sold out of Actinium Pharmaceuticals (ATNM) in Q4 2016, closing a stake of 21 shares — an estimated $1K sold.

US Bancorp first reported a position in ATNM in Q3 2016 and held it in 1 quarter. The position peaked at $1K in Q3 2016. 30 funds tracked by Wall St. Rank hold ATNM as of Q4 2016.

US Bancorp reported no remaining Actinium Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
US Bancorp sold 21 Actinium Pharmaceuticals shares in Q4 2016, an estimated $1K.
US Bancorp first reported a position in Actinium Pharmaceuticals in Q3 2016 and held it in 1 quarter.
US Bancorp's Actinium Pharmaceuticals position peaked at $1K in Q3 2016.
30 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q4 2016.

Based on US Bancorp's 13F filing for Q4 2016, filed 8 Feb 2017.